News
-
-
-
-
-
PRESS RELEASE
OSE Immunotherapeutics Announces Presentation of TEDOVA Phase 2 Topline Results of Tedopi® in Ovarian Cancer at the ASCO 2026 Meeting
OSE Immunotherapeutics announces topline results from TEDOVA Phase 2 trial of Tedopi® in Ovarian Cancer at ASCO 2026 Meeting. Presentation by lead investigator Alexandra Leary, MD, PhD -
-
-
PRESS RELEASE
Sartorius Stedim Biotech reports robust first-quarter results for fiscal 2026
Sartorius Stedim Biotech reports robust first-quarter results for fiscal 2026 with sales revenue up 7.9% in constant currencies. Profitability remains strong with a margin of 30.7% and net profit of 88 million euros -
-